1. Home
  2. JSPR vs VERU Comparison

JSPR vs VERU Comparison

Compare JSPR & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$1.55

Market Cap

43.7M

Sector

Health Care

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.61

Market Cap

42.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JSPR
VERU
Founded
2018
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.7M
42.2M
IPO Year
N/A
1990

Fundamental Metrics

Financial Performance
Metric
JSPR
VERU
Price
$1.55
$2.61
Analyst Decision
Buy
Strong Buy
Analyst Count
10
2
Target Price
$18.13
$22.50
AVG Volume (30 Days)
975.8K
144.1K
Earning Date
02-26-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.39
$2.10
52 Week High
$7.19
$7.40

Technical Indicators

Market Signals
Indicator
JSPR
VERU
Relative Strength Index (RSI) 43.80 52.31
Support Level $1.51 $2.46
Resistance Level $1.66 $2.84
Average True Range (ATR) 0.12 0.20
MACD 0.00 0.02
Stochastic Oscillator 45.19 56.23

Price Performance

Historical Comparison
JSPR
VERU

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: